SCHEMBL5262387

SCHEMBL5262387

CCN(CC)CCOc1ccc(Nc2ncc3ccc(=O)n(-c4ccccc4)c3n2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 9/20 0.73
CCND1 P24385 9/20 0.73
CCND2 P30279 9/20 0.73
CCND3 P30281 9/20 0.73
RIPK2 O43353 7/20 0.63
NOD2 Q9HC29 7/20 0.63
ACVR1 Q04771 6/20 0.63
WEE1 P30291 4/20 0.56
SRC P12931 3/20 0.56
FGFR1 P11362 2/20 0.56
CHEK1 O14757 1/20 0.56
JAK2 O60674 1/20 0.56
PRKD3 O94806 1/20 0.56
MAP4K4 O95819 1/20 0.56
PAK4 O96013 1/20 0.56
ABL1 P00519 1/20 0.56
EGFR P00533 1/20 0.56
NTRK1 P04629 1/20 0.56
LCK P06239 1/20 0.56
FYN P06241 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5266234 0.87 CDK4 (0.57) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL5266709 0.85 CDK4 (0.59) CDK4CCND1CCND2CCND3SRC
Hydrochloric Acid SCHEMBL30241083 0.84 CDK4 (0.78) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL4353287 0.84 CDK4 (1.00) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL5264440 0.83 CDK4 (1.00) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL5264317 0.82 CDK4 (0.73) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL5263418 0.81 CDK4 (1.00) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL5263497 0.81 CDK4 (0.93) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL5263834 0.81 CDK4 (1.00) CDK4CCND1CCND2CCND3RIPK2
SCHEMBL5262381 0.81 CDK4 (1.00) CDK4CCND1CCND2CCND3RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1806348-A2 Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation Warner-Lambert Company LLC (US) 2007-07-11 EP claimed
US-6498163-B1 POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS WARNER-LAMBERT COMPANY 2002-12-24 US claimed
EP-1806348-A2 Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation Warner-Lambert Company LLC (US) 2007-07-11 EP disclosed
US-20040224958-A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease BOOTH RICHARD JOHN (US) 2004-11-11 US disclosed
US-6498163-B1 POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS WARNER-LAMBERT COMPANY 2002-12-24 US disclosed
EP-1255755-A1 PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE WARNER-LAMBERT COMPANY (US) 2002-11-13 EP disclosed
WO-2001055148-A1 PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE WARNER-LAMBERT COMPANY (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224958-A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease CDK4, CDKL1, CCNT1 CDK4 1/4885CCND1 23/4885CCND2 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.